Earnings Release • Aug 7, 2007
Earnings Release
Open in ViewerOpens in native device viewer
Interim Report January – June 2007
Eucerin: Highly Effective Products. An International Success.
More and more consumers have sensitive skin. They need well-tolerated products that offer effective solutions for their special needs. For this reason the medical skin care market is growing strongly.
Eucerin is a leading brand in the area of dermocosmetics and the first choice of consumers in several countries. The products' excellent tolerance and effectiveness are continuously tested in clinical studies. We are expanding Eucerin's market position all over the world with successful innovations and an optimal presentation of our products.
| Beiersdorf at a Glance | ||
|---|---|---|
| in € million (unless otherwise stated) | Jan. 1–June 30, 2006 |
Jan. 1–June 30, 2007 |
| Sales | 2,609 | 2,850 |
| Change (nominal) | 7.2% | 9.2% |
| Change (adjusted for currency translation effects) | 6.2% | 10.6% |
| Consumer | 2,212 | 2,426 |
| tesa | 397 | 424 |
| Operating result (EBIT) | 263 | 315 |
| Operating result (EBIT, excluding special factors) | 321 | 373 |
| Profi t after tax | 518 | 206 |
| Profi t after tax (excluding special factors) | 197 | 244 |
| Return on sales after tax | 19.8% | 7.2% |
| Return on sales after tax (excluding special factors) | 7.6% | 8.6% |
| Earnings per share in € | 2.27 | 0.90 |
| Earnings per share in € (excluding special factors) | 0.86 | 1.07 |
| Gross cash fl ow | 234 | 251 |
| Capital expenditure (incl. fi nancial assets) | 49 | 46 |
| Research and development expenses | 54 | 61 |
| Employees (as of June 30) | 17,076 | 16,990 |
*Excluding special factors. For details on the special factors, please refer to our selected explanatory notes on page 18.
| Sales | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Apr. 1–June 30, 2006 |
Apr. 1–June 30, 2007 |
Jan. 1–June 30, 2006 |
Jan. 1–June 30, 2007 |
Change in % nominal adj. for curr. |
||||||
| (in € million) | % of total | % of total | % of total | % of total | trans. effects | |||||
| Consumer | 1,137 | 85.2 | 1,252 | 85.6 | 2,212 | 84.8 | 2,426 | 85.1 | 9.7 | 11.1 |
| tesa | 197 | 14.8 | 211 | 14.4 | 397 | 15.2 | 424 | 14.9 | 6.6 | 7.9 |
| Total | 1,334 | 100.0 | 1,463 | 100.0 | 2,609 | 100.0 | 2,850 | 100.0 | 9.2 | 10.6 |
| EBITDA | Change in % | |||||||||
| (in € million) | % of sales | % of sales | % of sales | % of sales | nominal | |||||
| Consumer | 127 | 11.1 | 154 | 12.3 | 295 | 13.3 | 324 | 13.4 | 10.1 | |
| tesa | 24 | 12.5 | 29 | 14.1 | 50 | 12.7 | 58 | 13.7 | 15.3 | |
| Total | 151 | 11.3 | 183 | 12.5 | 345 | 13.2 | 382 | 13.4 | 10.9 | |
| Operating Result (EBIT) | Change in % | |||||||||
| (in € million) | % of sales | % of sales | % of sales | % of sales | nominal | |||||
| Consumer | 83 | 7.3 | 119 | 9.5 | 226 | 10.2 | 268 | 11.1 | 18.9 | |
| Consumer (excluding special factors)* 141 | 12.4 | 167 | 13.3 | 284 | 12.8 | 326 | 13.4 | 14.9 | ||
| tesa | 18 | 9.2 | 24 | 11.3 | 37 | 9.4 | 47 | 11.0 | 24.3 | |
| Total | 101 | 7.6 | 143 | 9.8 | 263 | 10.1 | 315 | 11.1 | 19.7 | |
| Total (excluding special factors)* | 159 | 11.9 | 191 | 13.0 | 321 | 12.3 | 373 | 13.1 | 16.0 | |
| Gross Cash Flow | Change in % | |||||||||
| (in € million) | % of sales | % of sales | % of sales | % of sales | nominal | |||||
| Consumer | 72 | 6.3 | 95 | 7.6 | 197 | 8.9 | 209 | 8.6 | 6.6 | |
| tesa | 21 | 10.9 | 22 | 10.1 | 37 | 9.3 | 42 | 9.8 | 12.6 | |
| Total | 93 | 7.0 | 117 | 8.0 | 234 | 8.9 | 251 | 8.8 | 7.5 |
| Sales | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Apr. 1–June 30, 2006 |
Apr. 1–June 30, 2007 |
Jan. 1–June 30, 2006 |
Jan. 1–June 30, 2007 |
Change in % nominal adj. for curr. |
||||||
| (in € million) | % of total | % of total | % of total | % of total | trans. effects | |||||
| Europe | 1,027 | 77.0 | 1,077 | 73.6 | 1,961 | 75.2 | 2,084 | 73.1 | 6.2 | 6.1 |
| Americas | 160 | 12.0 | 188 | 12.8 | 343 | 13.1 | 375 | 13.2 | 9.5 | 15.9 |
| Africa/Asia/Australia | 147 | 11.0 | 198 | 13.6 | 305 | 11.7 | 391 | 13.7 | 28.3 | 34.3 |
| Total | 1,334 | 100.0 | 1,463 | 100.0 | 2,609 | 100.0 | 2,850 | 100.0 | 9.2 | 10.6 |
| Operating Result (EBIT) | Change in % | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| (in € million) | % of sales | % of sales | % of sales | % of sales | nominal | ||||
| Europe | 95 | 9.3 | 123 | 11.4 | 240 | 12.2 | 275 | 13.2 | 14.6 |
| Europe (excluding special factors)* | 153 | 14.9 | 171 | 15.8 | 298 | 15.2 | 333 | 16.0 | 11.6 |
| Americas | 1 | 0.4 | 5 | 2.8 | 5 | 1.6 | 11 | 3.0 | 106.7 |
| Africa/Asia/Australia | 5 | 3.4 | 15 | 7.5 | 18 | 5.8 | 29 | 7.4 | 62.4 |
| Total | 101 | 7.6 | 143 | 9.8 | 263 | 10.1 | 315 | 11.1 | 19.7 |
| Total (excluding special factors)* | 159 | 11.9 | 191 | 13.0 | 321 | 12.3 | 373 | 13.1 | 16.0 |
*For details on the special factors, please refer to our selected explanatory notes on page 18. Figures in percent are calculated based on thousands of euros.
APRIL
The NIVEA Temporary Shop opened its doors in Milan from April 14 to May 13, offering a beauty area in which consumers received advice from experts on topics such
as styling, and makeup. This short-term shop is a project from the creative NIVEA Lab, which implements unusual ideas and projects in order to set and develop new trends.
In the United States, retail group Wal-Mart presented Beiersdorf with its "Supplier of Excellence" award for the fi rst quarter of 2007. In Greece, NIVEA SUN was awarded the "Prix de Beauté 2007" as the best sun care product. In addition, the launch of NIVEA VISAGE DNAge day cream in Portugal won the "Master of Distribution 2007" prize in the "cosmetics
and perfume products" category.
Beiersdorf's new Sustainability Report has been available on the Internet since April. It shows in detail how the Company is fulfi lling its economic,
ecological, and social responsibilities, and answers key questions posed by stakeholders – from investors to consumers. A print version also summarizes the most important facts and fi gures.
Prof. W. H. Irwin McLean (Scotland) and Dr. Alan Irvine (Ireland) have been awarded this year's renowned Paul Gerson Unna Prize for their research into important genetic causes of neurodermatitis. The prize is awarded by Beiersdorf AG every two years for outstanding work in the fi eld of basic dermatological research. Worth €25,000, it is one of the biggest scientifi c prizes in the fi eld.
NIVEA India detailed the brand's plans for expansion in a press conference
with top fi nance and lifestyle journalists. The main topic was the launch of the NIVEA FOR MEN range, with the goal of driving forward sales growth in the men's care segment. The press conference is part of the PR activities specifi cally designed to raise awareness of NIVEA in the Indian media.
A record number of Internet users visited NIVEA websites worldwide in April 2007.
NIVEA now has local Internet presences featuring a uniform brand design in 48 countries. The newest version is the Indian website, which opens up the world of NIVEA to visitors using interactive advice modules, among other things.
Over the past two years, Beiersdorf has invested heavily in the growth of
NIVEA in China – with great success: NIVEA VISAGE increased its sales in 2006 by more than 50%. Within just three years, NIVEA FOR MEN has become number one in the men's face care segment.
In the course of a discussion forum tesa presented its innovative Holospot technology to international leaders at the G8 Summit in Heiligendamm (Germany). This provides effective protection against brand and product counterfeiting, an important topic at the summit. tesa Holospot allows a product's authenticity to be conclusively verifi ed. Its features range from those that can be seen to digitally encrypted information.
Beiersdorf is planning to transfer its production from Italy to Spain, Germany, and Poland. This measure is another step in the realignment of the Consumer Supply Chain. The Italian facility, located in Brembate near Milan, has 190 employees and primarily manufactures special products for NIVEA VISAGE, NIVEA body, and NIVEA SUN.
JUNE
In the second quarter of 2007, shares in the eurozone and the United States increased signifi cantly in value despite the clear rise in long-term investment returns. Against a backdrop of stable and in fact accelerating worldwide economic growth, many companies reported positive business developments in the fi rst months of the year. In spite of the upheavals in February, this positive news fl ow and the high level of merger and acquisition activity led to greater risk appetite among investors, and hence to rising share prices. This was refl ected on the German stock market by strong growth in the DAX, which broke through the 8,000 point mark for the fi rst time, closing the quarter slightly above that level.
The stocks in the European HPC (household and personal care) sector to which Beiersdorf belongs performed much less dynamically than the total market index for Germany. After initially developing in line with the total market index, the HPC index turned in a more neutral performance, closing the fi rst half of the year at a level that was improved but moderate in comparison.
Beiersdorf's share price outperformed the index at the beginning of the quarter. The Executive Board provided the fi nancial community with information about the Company's business development and the implementation of its Consumer Business Strategy at the Annual General Meeting in April and on publication of the fi rst quarter results in May. The rapid acceleration in growth and the continuing success of the launch of NIVEA VISAGE DNAge and the relaunch of NIVEA Hair Care were received very positively by the market, and caused our share price to climb temporarily to a new all-time high. In June, the CEO and the CFO held numerous discussions at an investors' conference in Paris. Management provided the market with additional information at road shows in London and Paris about Beiersdorf's strategy and business development. The Beiersdorf share closed the quarter on June 29 at €52.84, above its opening price.
Beiersdorf Share Price Performance April – June 2007
Sales growth of 10.6% EBIT margin (excluding special factors) climbs to 13.1% Profit after tax (excluding special factors) up significantly on previous year
In the fi rst half of the year, the Group achieved sales growth of 10.6% (adjusted for currency translation effects). The Consumer business segment contributed to this excellent result with sales up 11.1%, while tesa sales increased by 7.9%. At current exchange rates, sales rose by 9.2% to €2,850 million (previous year: €2,609 million).
| Income Statement | |||
|---|---|---|---|
| (in € million) | Jan. 1–June 30, 2006 |
Jan. 1–June 30, 2007 |
Change in % |
| Sales | 2,609 | 2,850 | 9.2 |
| Cost of goods sold | –864 | –920 | 6.4 |
| Gross profi t | 1,745 | 1,930 | 10.6 |
| Marketing and selling expenses | –1,217 | –1,342 | 10.3 |
| Research and development expenses | –54 | –61 | 14.0 |
| General and administrative expenses | –118 | –126 | 6.3 |
| Other operating expenses (net) | –35 | –28 | –17.7 |
| Operating result (EBIT, excluding special factors) | 321 | 373 | 16.0 |
| Expenses for the realignment of the Consumer Supply Chain |
–58 | –58 | - |
| Operating result (EBIT) | 263 | 315 | 19.7 |
| Income from the sale of BSN medical | 371 | - | - |
| Other fi nancial result | –2 | 14 | - |
| Profi t before tax | 632 | 329 | –48.0 |
| Taxes on income | –114 | –123 | 7.7 |
| Profi t after tax | 518 | 206 | –60.3 |
| Basic/diluted earnings per share (in €) | 2.27 | 0.90 | –60.5 |
The operating result excluding special factors increased from €321 million to €373 million. The corresponding EBIT margin rose from 12.3% to 13.1%. Expenses for the realignment of the Consumer Supply Chain in Europe were €58 million, as in the previous year, and include all measures announced to date or currently being implemented.
The other fi nancial result rose by €16 million to €14 million (previous year: €–2 million).
Profi t after tax amounted to €206 million (previous year: €518 million). Profi t after tax excluding special factors amounted to €244 million (previous year: €197 million); the corresponding return on sales after tax was 8.6% (previous year: 7.6%).
Earnings per share amounted to €0.90 (previous year: €2.27). Earnings per share excluding special factors rose to €1.07 (previous year: €0.86).
Consumer business segment up 11.1% Consumer EBIT margin (excluding special factors) climbs to 13.4%
| Consumer | ||||
|---|---|---|---|---|
| (Jan. – June) (in € million) |
Europe | Americas | Africa/Asia/ Australia |
Total |
| Sales 2007 | 1,763 | 332 | 331 | 2,426 |
| Change (adjusted for currency translation effects) |
5.8% | 18.0% | 38.9% | 11.1% |
| Change (nominal) | 5.9% | 11.5% | 32.8% | 9.7% |
| EBIT 2007* | 298 | 7 | 21 | 326 |
| EBIT margin 2007* | 16.9% | 2.2% | 6.2% | 13.4% |
| EBIT 2006* | 268 | 3 | 13 | 284 |
| EBIT margin 2006* | 16.1% | 1.0% | 5.0% | 12.8% |
*Excluding expenses for the realignment of the Consumer Supply Chain (Europe only).
Sales rose signifi cantly by 11.1% (adjusted for currency translation effects) in the fi rst half of the year. At current exchange rates, the Consumer business segment achieved sales growth of 9.7% to €2,426 million (previous year: €2,212 million). Strong double-digit growth was again seen in the Eastern Europe, Latin America, and Africa/Asia/Australia regions in particular.
Global NIVEA sales rose by 13.0%. This positive development was driven primarily by strong sales growth for NIVEA body, NIVEA deodorant, NIVEA VISAGE, and NIVEA FOR MEN. The successful relaunch of NIVEA Hair Care continued. NIVEA products generated sales of €1,800 million in the fi rst half of the year. Sales growth for the Eucerin and la prairie brands remained above average.
At €326 million (previous year: €284 million), Consumer EBIT (excluding special factors) increased faster than sales. The operating EBIT margin rose to 13.4% (previous year: 12.8%).
| Consumer Sales in Europe (Jan. – June) (in € million) |
Germany | Western Europe (not including Germany) |
Eastern Europe | Total |
|---|---|---|---|---|
| Sales 2007 | 496 | 985 | 282 | 1,763 |
| Change (adjusted for currency translation effects) |
–3.1% | 4.5% | 33.0% | 5.8% |
| Change (nominal) | –3.1% | 4.3% | 34.8% | 5.9% |
In Europe, sales in the Consumer business segment grew by 5.8% in comparison with the previous year (adjusted for currency translation effects). At current exchange rates, sales rose by 5.9% to €1,763 million (previous year: €1,665 million).
Sales to customers in Germany were 4.3% above the previous year. Our NIVEA body, NIVEA deodorant, and NIVEA Bath Care brands accounted for a signifi cant share of sales growth. NIVEA body continued to benefi t from the successful launch of NIVEA Good-bye Cellulite, and NIVEA Summer Beauty also performed well. Our Eucerin brand again enjoyed above-average growth in the pharmacy business. Beiersdorf AG's export sales, to the Middle East and the member countries of the Commonwealth of Independent States (CIS) in particular, were transferred to our affi liates in Dubai and Russia respectively starting in the third quarter of 2006. This led to a corresponding decrease in exports from Germany to these countries.
Sales in Western Europe rose by 4.5% (adjusted for currency translation effects). The La Prairie Group (+17.3%), Greece (+15.5%), and the UK/Ireland Group (+7.4%) made particularly strong contributions to this. NIVEA deodorant, NIVEA VISAGE – among other products the strong performance of the NIVEA VISAGE DNAge skin care range – and NIVEA Hair Care contributed positively to sales growth. Our la prairie and Eucerin brands again generated double-digit growth rates.
Sales growth in Eastern Europe remained extremely strong with a rise of 33.0%. We recorded doubledigit growth rates in Russia, Poland, and in all other major Eastern European markets.
In Russia, NIVEA FOR MEN, NIVEA Hair Care, and NIVEA deodorant were the main growth drivers. In Poland, NIVEA deodorant, NIVEA body, and NIVEA Hair Care performed particularly well. The transfer of Beiersdorf AG's (Germany) export sales to the Russian affi liate contributed approximately six percentage points to this region's growth rate.
At €298 million (previous year: €268 million), Consumer EBIT in Europe (excluding special factors) increased faster than sales. The corresponding EBIT margin rose to 16.9% (previous year: 16.1%).
| Consumer Sales in the Americas (Jan. – June) (in € million) |
North America | Latin America | Total |
|---|---|---|---|
| Sales 2007 | 168 | 164 | 332 |
| Change (adjusted for currency translation effects) |
9.9% | 28.1% | 18.0% |
| Change (nominal) | 2.0% | 23.3% | 11.5% |
In the Americas region, sales increased by 18.0% (adjusted for currency translation effects). At current exchange rates, sales amounted to €332 million, up 11.5% on the previous year (€298 million).
In North America, sales (adjusted for currency translation effects) were up 9.9% on the prior-year period. The continuing success of the NIVEA body relaunch is largely responsible for this. In addition, our Eucerin brand performed extremely well. The sale of the low-margin, slow-growing Curad brand plaster business in the United States in April 2007 slightly reduced the strong growth rate in North America.
We recorded 28.1% sales growth in Latin America (adjusted for currency translation effects). All major markets contributed to this development with double-digit growth. In addition to the key markets of Mexico (+19.3%) and Brazil (+38.3%), Argentina (+55.1%) and Venezuela (+45.3%) in particular recorded strong growth rates. NIVEA deodorant, NIVEA VISAGE, and NIVEA Bath Care performed especially well in this region.
Consumer EBIT in America rose to €7 million (previous year: €3 million). The EBIT margin was 2.2% (previous year: 1.0%).
| Consumer Sales in Africa/Asia/Australia | |
|---|---|
| (Jan. – June) (in € million) |
Africa/Asia/ Australia |
| Sales 2007 | 331 |
| Change (adjusted for currency translation effects) |
38.9% |
| Change (nominal) | 32.8% |
At 38.9%, Africa/Asia/Australia achieved excellent sales growth (adjusted for currency translation effects). At current exchange rates, sales amounted to €331 million, up 32.8% on the previous year (€249 million).
South Africa (+57.2%), China (+40.1%), and Thailand (+28.7%) made particularly strong contributions to our rapid sales growth. NIVEA body and NIVEA deodorant recorded signifi cant growth increases in South Africa. In China, growth was driven primarily by the performance of NIVEA VISAGE and NIVEA FOR MEN. Thailand recorded high sales growth in almost all product categories. In Japan, sales increased by 5.5% (adjusted for currency translation effects), thanks especially to our 8x4 brand's excellent positioning on the Japanese deodorant market, but also to increases in sales of NIVEA SUN and NIVEA FOR MEN. In India, we are building our business as planned and recording high growth rates, although these are still based on relatively small sales fi gures in absolute terms.
The transfer of export sales from Beiersdorf AG (Germany) to our company in Dubai, formed in 2006, contributed approximately 18 percentage points of the growth in this region.
Consumer EBIT for this region climbed to €21 million (previous year: €13 million). The EBIT margin was 6.2% (previous year: 5.0%).
| tesa | ||||
|---|---|---|---|---|
| (Jan. – June) | Europe | Americas | Africa/Asia/ | Total |
| (in € million) | Australia | |||
| Sales 2007 | 320 | 44 | 60 | 424 |
| Change (adjusted for | ||||
| currency translation effects) | 7.8% | 1.9% | 13.4% | 7.9% |
| Change (nominal) | 8.0% | –3.8% | 8.1% | 6.6% |
| EBIT 2007 | 35 | 4 | 8 | 47 |
| EBIT margin 2007 | 10.8% | 9.0% | 13.7% | 11.0% |
| EBIT 2006 | 30 | 2 | 5 | 37 |
| EBIT margin 2006 | 10.0% | 5.8% | 9.4% | 9.4% |
tesa sales were up 7.9% (adjusted for currency translation effects) on the previous year. At current exchange rates, tesa achieved sales of €424 million, an increase of 6.6% in comparison with the previous year.
This positive trend continued in both tesa's industrial and consumer businesses in the second quarter. In the consumer business, all regions recorded increases as against 2006, with both Northern Europe and Eastern Europe achieving double-digit sales growth.
tesa also performed extremely well in the industrial business. Both its industrial customer business and its direct business grew impressively, with the largest sales growth again attributed to electrical and electronics industry customers.
The Eastern European (+19.3%) and Africa/Asia/Australia (+13.4%) regions in particular recorded double-digit sales growth in the tesa segment (adjusted for currency translation effects). The positive development in the industrial sector (+7.8%) and in the consumer business (+5.9%) in the Central European region is also encouraging.
EBIT climbed to €47 million (previous year: €37 million), while the EBIT margin increased to 11.0% (previous year: 9.4%).
| Balance Sheet | |||
|---|---|---|---|
| Assets (in € million) | Dec. 31, 2006 | Jun. 30, 2006 | Jun.30,2007 |
| Non-current assets | 814 | 904 | 792 |
| Inventories | 548 | 560 | 570 |
| Other current assets | 904 | 1,006 | 1,137 |
| Cash and cash equivalents | 1,230 | 938 | 1,217 |
| 3,496 | 3,408 | 3,716 | |
| Equity and liabilities (in € million) | Dec. 31, 2006 | Jun. 30, 2006 | Jun.30,2007 |
| Equity | 1,790 | 1,640 | 1,850 |
| Non-current liabilities | 547 | 599 | 527 |
| Current liabilities | 1,159 | 1,169 | 1,339 |
At €792 million, non-current assets as of June 30 were signifi cantly below the previous year's level, as well as below the fi gures at the end of 2006. As part of the realignment of the Consumer Supply Chain, production and logistics locations were sold or impaired at fair value. In the fi rst half of 2007, capital expenditure excluding fi nancial assets amounted to €45 million (previous year: €44 million). €37 million (previous year: €34 million) of this fi gure was attributable to the Consumer business segment and €8 million (previous year: €10 million) to tesa. Depreciation and impairment losses amounted to €67 million (previous year: €82 million). At €570 million, inventories were only slightly higher than in the previous year (€560 million), despite the expansion of business activities. The positive sales trend resulted in higher trade receivables and thus to a signifi cant increase in other current assets to €1,137 million.
There have only been minor changes in non-current liabilities since December 31, 2006. The increase in other provisions resulting from operating activities and higher trade payables caused current liabilities to swell to €1,339 million.
| Financing Structure | |||
|---|---|---|---|
| Dec. 31, 2006 | 51% | 16% | 33% |
| Jun. 30, 2006 | 48% | 18% | 34% |
| Jun. 30, 2007 | 50% | 14% | 36% |
Equity Non-current liabilities Current liabilities
| Cash Flow Statement (in € million) |
Jan. 1–June 30, 2006 |
Jan. 1–June 30, 2007 |
|---|---|---|
| Cash and cash equivalents as of Jan. 1 | 483 | 1,230 |
| Gross cash fl ow | 234 | 251 |
| Change in working capital | –15 | –101 |
| Net cash fl ow from operating activities | 219 | 150 |
| Net cash fl ow from investing activities | 409 | –1 |
| Free cash fl ow | 628 | 149 |
| Net cash fl ow from fi nancing activities | –165 | –161 |
| Exchange rate and other changes | –8 | –1 |
| Net change in cash and cash equivalents | 455 | –13 |
| Cash and cash equivalents as of June 30 | 938 | 1,217 |
Gross cash fl ow amounted to €251 million. The net cash outfl ow from changes in working capital amounted to €101 million. This was primarily due to an increase in trade receivables caused by positive business development. Overall, net cash fl ow from operating activities amounted to €150 million. Net cash fl ow from investing activities amounted to €–1 million. Capital expenditure including fi nancial assets (€46 million) were matched by €45 million in interest receivables and other cash infl ows. In the previous year, this position included cash infl ows from the sale of our investment in BSN medical (€433 million). Free cash fl ow reached €149 million. The net cash outfl ow from fi nancing activities amounted to €161 million, due to the dividend payment of €136 million as well as interest and other fi nancing expenses in the amount of €25 million. Cash and cash equivalents totaled €1,217 million.
The number of employees fell by 182 to 16,990 compared with the fi gure of December 31, 2006. As of June 30, 13,201 employees worked in the Consumer business segment and 3,789 at tesa.
As part of the realignment of the Consumer Supply Chain, Beiersdorf is planning to transfer production from the facility owned by its Italian affi liate to the existing Beiersdorf production locations in Spain, Germany, and Poland.
On July 6, 2007, after the balance sheet date, the Bundesrat (Upper House of the German Parliament) approved the Unternehmensteuerreformgesetz (Corporate Taxation Reform Act). In accordance with IFRSs, the applicable tax rates as of the balance sheet date are used to calculate the Group's deferred taxes. The tax implications of the reform are thus not yet refl ected in the half-yearly fi nancial statements. With effect from the third quarter, we expect the recalculation of deferred taxes to impact profi t after tax positively.
For more information on opportunities and risks, please refer to our Risk Report in the Combined Management Report of Beiersdorf AG and the Group as of December 31, 2006. There were no changes in opportunities and risks during the fi rst half year.
We expect the positive macroeconomic trends to continue in fi scal year 2007. Our assessment of future developments is based on the assumption that current growth rates will be maintained.
The global cosmetics market is expected to continue its long-term trend growth of 3% to 4%. Despite some positive developments, we continue to anticipate moderate growth in the major markets of Western Europe. On the other hand, we expect signifi cant growth increases in Eastern Europe, Latin America, and Asia.
For the industry and consumer markets that are relevant to tesa, we expect growth rates to remain unchanged at 3% to 4%, although regional developments may vary substantially.
For the raw materials and procurement market, we expect raw material prices to trend upwards as the year continues, also driven by the robust global economy.
After an excellent fi rst half of 2007, the Beiersdorf Group expects to outperform the market in terms of sales growth.
The EBIT margin (excluding special factors) should increase further. EBIT will continue to be impacted by expenses of approximately €70 million relating to the realignment of the Consumer Supply Chain this year.
We are forecasting a disproportionately high increase in profi t after tax (excluding special factors), resulting in a further improvement in the return on sales after tax. Due to the 2008 corporate tax reform in Germany adopted in July 2007, we expect the recalculation of deferred taxes to have an additional positive effect on profi t after tax. This effect will be recognized for the fi rst time in the interim fi nancial statements as of September 30, 2007.
Based on the sustained growth in the fi rst half of the year, we expect sales growth (adjusted for currency translation effects) for the entire year in the Consumer business segment to be at the top end of the 7% to 8% target range. We continue to forecast especially strong growth rates in China, Russia, Brazil, and India.
The Consumer business segment's EBIT margin (excluding special factors) will continue to increase.
The tesa business segment should outperform the market in terms of sales growth, and further increase its EBIT margin.
| Income Statement | ||||
|---|---|---|---|---|
| Apr. 1–June 30, | Apr. 1–June 30, | Jan. 1–June 30, | Jan. 1–June 30, | |
| (in € million) | 2006 | 2007 | 2006 | 2007 |
| Sales | 1,334 | 1,463 | 2,609 | 2,850 |
| Cost of goods sold | –443 | –486 | –864 | –920 |
| Gross profi t | 891 | 977 | 1,745 | 1,930 |
| Marketing and selling expenses | –627 | –685 | –1,217 | –1,342 |
| Research and development expenses | –27 | –31 | –54 | –61 |
| General and administrative expenses | –58 | –62 | –118 | –126 |
| Other operating expenses (net) | –20 | –8 | –35 | –28 |
| Operating result (EBIT, excluding special factors) | 159 | 191 | 321 | 373 |
| Expenses for the realignment of the Consumer Supply Chain | –58 | –48 | –58 | –58 |
| Operating result (EBIT) | 101 | 143 | 263 | 315 |
| Income from the sale of BSN medical | - | - | 371 | - |
| Other fi nancial result | –2 | 8 | –2 | 14 |
| Profi t before tax | 99 | 151 | 632 | 329 |
| Taxes on income | –43 | –57 | –114 | –123 |
| Profi t after tax | 56 | 94 | 518 | 206 |
| Profi t attributable to equity holders | 55 | 93 | 516 | 204 |
| Profi t attributable to minority interests | 1 | 1 | 2 | 2 |
| Basic/diluted earnings per share (in €) | 0.24 | 0.41 | 2.27 | 0.90 |
| Balance Sheet | |||
|---|---|---|---|
| Assets (in € million) | Dec. 31, 2006 | June 30, 2006 | June 30, 2007 |
| Intangible assets | 30 | 29 | 28 |
| Property, plant, and equipment | 740 | 830 | 717 |
| Other non-current assets | 12 | 17 | 13 |
| Deferred tax assets | 32 | 28 | 34 |
| Non-current assets | 814 | 904 | 792 |
| Inventories | 548 | 560 | 570 |
| Trade receivables | 727 | 845 | 937 |
| Income tax receivables | 25 | 23 | 19 |
| Other current assets | 116 | 138 | 179 |
| Cash and cash equivalents | 1,230 | 938 | 1,217 |
| Non-current assets and disposal groups held for sale | 36 | - | 2 |
| Current assets | 2,682 | 2,504 | 2,924 |
| 3,496 | 3,408 | 3,716 | |
| Equity and liabilities (in € million) | Dec. 31, 2006 | June 30, 2006 | June 30, 2007 |
| Equity attributable to equity holders of Beiersdorf AG | 1,781 | 1,633 | 1,843 |
| Minority interests | 9 | 7 | 7 |
| Equity | 1,790 | 1,640 | 1,850 |
| Non-current provisions | 419 | 436 | 412 |
| Non-current fi nancial liabilities | 8 | 24 | 7 |
| Other non-current liabilities | 8 | 6 | 10 |
| Deferred tax liabilities | 112 | 133 | 98 |
| Non-current liabilities | 547 | 599 | 527 |
| Current provisions | 469 | 542 | 619 |
| Trade payables | 485 | 397 | 518 |
| Current fi nancial liabilities | 62 | 63 | 56 |
| Other current liabilities | 120 | 167 | 146 |
| Liabilities held for sale | 23 | - | - |
| Current liabilities | 1,159 | 1,169 | 1,339 |
| 3,496 | 3,408 | 3,716 |
| Cash Flow Statement | ||
|---|---|---|
| (in € million) | Jan. 1–June 30, 2006 |
Jan. 1–June 30, 2007 |
| Cash and cash equivalents as of Jan. 1 | 483 | 1,230 |
| Operating result (EBIT) | 263 | 315 |
| Income taxes paid | –114 | –113 |
| Depreciation and amortization | 82 | 67 |
| Change in non-current provisions (excluding interest) | 3 | –8 |
| Gain/loss on disposal of property, plant, and equipment and intangible assets | - | –10 |
| Gross cash fl ow | 234 | 251 |
| Change in inventories | –24 | –22 |
| Change in trade receivables and other assets | –153 | –246 |
| Change in liabilities and current provisions | 162 | 167 |
| Net cash fl ow from operating activities | 219 | 150 |
| Investments | –49 | –46 |
| Proceeds from divestments | 9 | 14 |
| Proceeds from the sale of BSN medical | 433 | - |
| Proceeds from interest, dividends, and other fi nancing activities | 16 | 31 |
| Net cash fl ow from investing activities | 409 | –1 |
| Free cash fl ow | 628 | 149 |
| Change in fi nancial liabilities | –16 | –6 |
| Interest and other fi nancing expenses paid | –20 | –19 |
| Cash dividends paid (Beiersdorf AG) | –129 | –136 |
| Net cash fl ow from fi nancing activities | –165 | –161 |
| Exchange rate and other changes | –8 | –1 |
| Net change in cash and cash equivalents | 455 | –13 |
| Cash and cash equivalents as of June 30 | 938 | 1,217 |
| Other equity | |||||||
|---|---|---|---|---|---|---|---|
| January – June 2007 (in € million) |
Share capital |
Additional paid-in capital |
Retained earnings |
Currency translation adjustment |
Other changes |
Minority interests |
Total |
| Jan. 1, 2007 | 252 | 47 | 1,587 | –93 | –12 | 9 | 1,790 |
| Net result from cash fl ow hedges | - | - | - | - | –1 | - | –1 |
| Currency translation adjustment | - | - | - | –14 | - | - | –14 |
| Other changes | - | - | –5 | - | 14 | –4 | 5 |
| Total income and expenses recognized directly in equity |
- | - | –5 | –14 | 13 | –4 | –10 |
| Dividend of Beiersdorf AG for previous year | - | - | –136 | - | - | - | –136 |
| Profi t after tax | - | - | 204 | - | - | 2 | 206 |
| June 30, 2007 | 252 | 47 | 1,650 | –107 | 1 | 7 | 1,850 |
| January – June 2006 | |||||||
| Jan. 1, 2006 | 215 | 47 | 1,096 | –62 | –16 | 13 | 1,293 |
| Net result from cash fl ow hedges | - | - | - | - | 6 | - | 6 |
| Currency translation adjustment | - | - | - | –31 | - | –1 | –32 |
| Other changes | 37 | - | –37 | - | –9 | –7 | –16 |
| Total income and expenses recognized directly in equity |
37 | 0 | –37 | –31 | –3 | –8 | –42 |
| Dividend of Beiersdorf AG for previous year | - | - | –129 | - | - | - | –129 |
| Profi t after tax | - | - | 516 | - | - | 2 | 518 |
| June 30, 2006 | 252 | 47 | 1,446 | –93 | –19 | 7 | 1,640 |
The registered offi ce of Beiersdorf AG is at Unnastrasse 48 in Hamburg (Germany) and the Company is registered with the commercial register of the Hamburg Local Court under the number HRB 1787. The activities of Beiersdorf AG and its affi liates ("Beiersdorf Group") consist primarily of the manufacture and distribution of branded consumer goods in the areas of skin and beauty care, and of the manufacture and distribution of technical adhesive tapes.
The interim consolidated fi nancial statements for the period from January 1 to June 30, 2007, were prepared in accordance with IAS 34 "Interim Financial Reporting." The interim consolidated fi nancial statements should be read in conjunction with the consolidated fi nancial statements as of December 31, 2006.
The fi gures disclosed in this interim report were prepared in accordance with International Financial Reporting Standards (IFRSs). The same accounting policies were used in the interim consolidated fi nancial statements as in the annual consolidated fi nancial statements for 2006. The interim report was not audited or limitedly reviewed.
The following table shows a reconciliation of earnings with regard to the special factors that affected earnings in the period under review and the prior-year period:
| Reconciliation of Profit After Tax | |||
|---|---|---|---|
| Jan. 1–June 30, 2006 (in € million) | According to P&L | Special factors | Adjusted |
| EBIT | 263 | 58 | 321 |
| Financial result | 369 | –371 | –2 |
| Taxes | –114 | –8 | –122 |
| Profi t after tax | 518 | –321 | 197 |
| Jan. 1–June 30, 2007 | According to P&L | Special factors | Adjusted |
| EBIT | 315 | 58 | 373 |
| Financial result | 14 | - | 14 |
| Taxes | –123 | –20 | –143 |
| Profi t after tax | 206 | 38 | 244 |
Special factors affecting EBIT relate to expenses for the realignment of the Consumer Supply Chain in Europe. The special factor affecting the fi nancial result relates to the income from the sale of the shares of BSN medical in the prior-year period.
Please refer to the consolidated fi nancial statements as of December 31, 2006, for related party disclosures. There were no signifi cant changes in the fi rst half of 2007.
The declaration of compliance issued by the Supervisory Board and the Executive Board for fi scal year 2006 regarding the recommendations of the German Corporate Governance Code in accordance with §161 Aktiengesetz (German Stock Corporation Act) was published at the end of December 2006 and is permanently available on our website at www.Beiersdorf.com.
No signifi cant events occurred after the balance sheet date that would have a material effect on the Beiersdorf Group's business developments.
To the best of our knowledge, and in accordance with the applicable reporting principles for interim fi nancial reporting, the interim consolidated fi nancial statements give a true and fair view of the assets, liabilities, fi nancial position, and profi t or loss of the group, and the interim management report of the group includes a fair review of the development and performance of the business and the position of the group, together with a description of the principal opportunities and risks associated with the expected development of the group for the remaining months of the fi scal year.
Hamburg, August 2007 Beiersdorf AG The Executive Board
| November 6, 2007 | Interim Report January to September 2007, Financial Analyst Meeting |
|---|---|
| January 2008 | Publication of Preliminary Group Results |
| February/March 2008 |
Publication of Annual Report 2007, Annual Accounts Press Conference, Financial Analyst Meeting |
| April 30, 2008 | Annual General Meeting |
| May 2008 | Interim Report January to March 2008 |
| August 2008 | Interim Report January to June 2008 |
| November 2008 | Interim Report January to September 2008, Financial Analyst Meeting |
Beiersdorf Aktiengesellschaft, Global Corporate Identity & Information, Unnastrasse 48, 20245 Hamburg, Germany Telephone: +49 40 4909-0, Fax: +49 40 4909-3434
Press and PR: Telephone +49 40 4909-2332, E-mail: [email protected] Investor Relations: Telephone +49 40 4909-5000, E-mail: [email protected] Beiersdorf on the Internet: www.Beiersdorf.com
@ The interim report is also available in German and a digital version is available on the Internet at www.Beiersdorf.com/interim_report.
Commercial Register Hamburg HRB 1787
Passion for Skin & Beauty Care
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.